X
Log In
Username or E-mail:
Password:
EULA
Log In
Forgot Password
Sign Up
Sign Up
Username:
E-mail:
Password:
EULA
Sign Up
Forgot Password
Already a Member
Username or E-mail
Send Forgot Mail
Back to Login
EULA
X
Share This!
Sign Up
Log In
Logout
X
English Türkçe

PPBT

Closed

Purple Biotech

2.375
+0.030 (+1.28%)
Last Update: 01 Jul 2025 23:00:00
Yesterday: 2.345
Day's Range: 2.26 - 2.39
Send
When Written:
 
1.98
Purple Biotech is a clinical-stage biotechnology company that focuses on developing innovative cancer treatments. The company was founded in 2010 and is headquartered in Rehovot, Israel.

Purple Biotech's lead product candidate is NT219, a small molecule inhibitor of several oncogenic pathways. NT219 has shown promising results in preclinical studies and is currently being evaluated in clinical trials for the treatment of solid tumors and hematological malignancies.

In addition to NT219, Purple Biotech is also developing a pipeline of other oncology therapeutics, including a novel CAR-T therapy for the treatment of multiple myeloma.

Purple Biotech has partnerships with several leading pharmaceutical companies, including Bristol Myers Squibb, Merck, and Roche. The company is also backed by a strong group of investors, including OrbiMed, Novartis Venture Fund, and Johnson & Johnson Innovation.

Overall, Purple Biotech is focused on leveraging its innovative science and strategic partnerships to develop new treatments for cancer patients.

Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
Contact with us

Mail:
Message:
Cancel
Send
IP Adresiniz:216.73.216.11
X